학술논문
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Original Article
Original Article
Document Type
Report
Author
Source
The New England Journal of Medicine. May 7, 2020, Vol. 382 Issue 19, p1800, 11 p.
Subject
Language
English
ISSN
0028-4793
Abstract
Ruxolitinib therapy for acute graft-versus-host disease led to significant improvements in efficacy outcomes. In 154 patients assigned to the ruxolitinib group and 155 to the control group, overall response at day 28 was 62% (96 patients) in the ruxolitinib group and 39% (61 patients) in the control group. The therapy led to a higher incidence of thrombocytopenia, the most frequent toxic effect.